Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

INTRODUCTION: Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargiulo, Luigi, Ibba, Luciano, Pavia, Giulia, Vignoli, Carlo Alberto, Piscazzi, Francesco, Valenti, Mario, Sanna, Federica, Perugini, Chiara, Avagliano, Jessica, Costanzo, Antonio, Narcisi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443623/
https://www.ncbi.nlm.nih.gov/pubmed/36063283
http://dx.doi.org/10.1007/s13555-022-00795-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443623/
https://www.ncbi.nlm.nih.gov/pubmed/36063283
http://dx.doi.org/10.1007/s13555-022-00795-x

Ejemplares similares